Trials / Unknown
UnknownNCT05143892
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
Study on Avatrombopag for the Promotion of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of avatrombopag for the promotion of platelet engraftment after Allo-HSCT.
Detailed description
Patients with thrombocytopenia (PLT\<20×10\^9/L) after allogenic hematopoietic stem cell transplantation (Allo-HSCT) who meet Eligibility Criteria were assigned into the avatrombopag group for 4 weeks' treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avatrombopag | Avatrombopag administered at the described frequency to achieve a target platelet count |
| OTHER | Supportive care | Supportive care other than TPO-RAs or recombinant human thrombopoietin. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-12-31
- Completion
- 2023-11-30
- First posted
- 2021-12-03
- Last updated
- 2022-12-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05143892. Inclusion in this directory is not an endorsement.